DNA/MVA vaccine: Phase I/II started

GeoVax began an open-label, U.S. Phase I/II trial to evaluate DNA/MVA vaccine in about 10 HIV-1 infected adults with suppressed viremia who started antiretroviral therapy within 18 months of a negativ...